A Phase 1 interventional study of Apremilast in Healthy Volunteer, sponsored by Amgen. Completed at 2 sites in United States. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-04-14.
Sponsored by Amgen · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of the study is to evaluate the effects of age and sex on the pharmacokinetics and safety of a single oral dose of 30 mg apremilast in healthy adults.
This is an open-label, parallel group study where eligible elderly adults (aged 65-85 years inclusive) and younger adults (aged 18-55 years inclusive) and who are matched to the elderly participants by sex and body mass index (BMI) (± 10%) will receive a single dose of 30 mg apremilast under fasting conditions.
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
Inclusion Criteria for elderly group
Inclusion Criteria for younger group:
Females who are able to become pregnant have a negative pregnancy test at screening and baseline, and must agree to use one of the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants aged 65 to 85 years received a single oral dose of 30 mg apremilast on Day 1.
Drug: Apremilast
Participants aged 18 to 55 years received a single oral dose of 30 mg apremilast on Day 1.
Drug: Apremilast
One oral 30 mg dose of apremilast
Also known as: CC-10004, Otezla®
Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC0-t) of Apremilast
The lower limit of quantitation for apremilast plasma concentrations was 1.0 ng/mL. AUC0-t was calculated using the linear trapezoidal method when concentrations were increasing and the logarithmic trapezoidal method when concentrations were decreasing.
Time frame: Day 1 predose and at 0.5, 1, 1.5, 2, 2.5, 3, 5, 8, 12, 24, 36, and 48 hours after dosing.
AUC From Time Zero to Time of Last Quantifiable Concentration (AUC0-t) of Apremilast by Sex
The lower limit of quantitation for apremilast plasma concentrations was 1.0 ng/mL. AUC0-t was calculated using the linear trapezoidal method when concentrations were increasing and the logarithmic trapezoidal method when concentrations were decreasing.
Time frame: Day 1 predose and at 0.5, 1, 1.5, 2, 2.5, 3, 5, 8, 12, 24, 36, and 48 hours after dosing.
Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-∞) of Apremilast
The lower limit of quantitation for apremilast plasma concentrations was 1.0 ng/mL.
Time frame: Day 1 predose and at 0.5, 1, 1.5, 2, 2.5, 3, 5, 8, 12, 24, 36, and 48 hours after dosing.
AUC From Time Zero Extrapolated to Infinity (AUC0-∞) of Apremilast by Sex
The lower limit of quantitation for apremilast plasma concentrations was 1.0 ng/mL.
Time frame: Day 1 predose and at 0.5, 1, 1.5, 2, 2.5, 3, 5, 8, 12, 24, 36, and 48 hours after dosing.
Maximum Observed Plasma Concentration (Cmax) of Apremilast
The lower limit of quantitation for apremilast plasma concentrations was 1.0 ng/mL.
Time frame: Day 1 predose and at 0.5, 1, 1.5, 2, 2.5, 3, 5, 8, 12, 24, 36, and 48 hours after dosing.
Maximum Observed Plasma Concentration of Apremilast by Sex
The lower limit of quantitation for apremilast plasma concentrations was 1.0 ng/mL.
Time frame: Day 1 predose and at 0.5, 1, 1.5, 2, 2.5, 3, 5, 8, 12, 24, 36, and 48 hours after dosing.
Time to Maximum Observed Plasma Concentration (Tmax) of Apremilast
The lower limit of quantitation for apremilast plasma concentrations was 1.0 ng/mL.
Time frame: Day 1 predose and at 0.5, 1, 1.5, 2, 2.5, 3, 5, 8, 12, 24, 36, and 48 hours after dosing.
Time to Maximum Observed Plasma Concentration (Tmax) of Apremilast by Sex
The lower limit of quantitation for apremilast plasma concentrations was 1.0 ng/mL.
Time frame: Day 1 predose and at 0.5, 1, 1.5, 2, 2.5, 3, 5, 8, 12, 24, 36, and 48 hours after dosing.
Estimate of Terminal Elimination Half-life of Apremilast in Plasma (t1/2)
Time frame: Day 1 predose and at 0.5, 1, 1.5, 2, 2.5, 3, 5, 8, 12, 24, 36, and 48 hours after dosing.
Estimate of Terminal Elimination Half-life of Apremilast in Plasma by Sex
Time frame: Day 1 predose and at 0.5, 1, 1.5, 2, 2.5, 3, 5, 8, 12, 24, 36, and 48 hours after dosing.
Apparent Total Plasma Clearance When Dosed Orally (CL/F) of Apremilast
Time frame: Day 1 predose and at 0.5, 1, 1.5, 2, 2.5, 3, 5, 8, 12, 24, 36, and 48 hours after dosing.
Apparent Total Plasma Clearance When Dosed Orally of Apremilast by Sex
Time frame: Day 1 predose and at 0.5, 1, 1.5, 2, 2.5, 3, 5, 8, 12, 24, 36, and 48 hours after dosing.
Apparent Total Volume of Distribution When Dosed Orally (Vz/F) of Apremilast
Time frame: Day 1 predose and at 0.5, 1, 1.5, 2, 2.5, 3, 5, 8, 12, 24, 36, and 48 hours after dosing.
Apparent Total Volume of Distribution When Dosed Orally (Vz/F) of Apremilast by Sex
Time frame: Day 1 predose and at 0.5, 1, 1.5, 2, 2.5, 3, 5, 8, 12, 24, 36, and 48 hours after dosing.
Number of Participants With Adverse Events
An adverse event (AE) was any noxious, unintended, or untoward medical occurrence that appeared or worsened in a participant during the course of the study. It could have been a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health including laboratory test values, regardless of etiology. Any worsening (i.e., any clinically significant adverse change in the frequency or intensity of a pre-existing condition) was considered an AE.
Time frame: From first dose of study drug up to 11 days
This study was conducted at two clinical research sites in the United States.
| Milestone | Young: Apremilast 30 mg | Elderly: Apremilast 30 mg |
|---|---|---|
| Started | 18 | 18 |
| Completed | 18 | 18 |
| Not completed | 0 | 0 |
The lower limit of quantitation for apremilast plasma concentrations was 1.0 ng/mL. AUC0-t was calculated using the linear trapezoidal method when concentrations were increasing and the logarithmic trapezoidal method when concentrations were decreasing.
| h*ng/mL | Young: Apremilast | Elderly: Apremilast |
|---|---|---|
| Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC0-t) of Apremilast | 2832 ± 28.1 | 3235 ± 40.3 |
An adverse event (AE) was any noxious, unintended, or untoward medical occurrence that appeared or worsened in a participant during the course of the study. It could have been a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health including laboratory test values, regardless of etiology. Any worsening (i.e., any clinically significant adverse change in the frequency or intensity of a pre-existing condition) was considered an AE.
| Participants | Young Males | Young Females | Elderly Males | Elderly Females |
|---|---|---|---|---|
| Any adverse event | 2 | 1 | 2 | 5 |
| Adverse event related to study drug | 2 | 1 | 0 | 1 |
| Serious adverse events | 0 | 0 | 0 | 0 |
| Serious adverse events related to study drug | 0 | 0 | 0 | 0 |
| Discontinued due to adverse event | 0 | 0 | 0 | 0 |
| Discontinued due to adverse event related to study drug | 0 | 0 | 0 | 0 |
The lower limit of quantitation for apremilast plasma concentrations was 1.0 ng/mL. AUC0-t was calculated using the linear trapezoidal method when concentrations were increasing and the logarithmic trapezoidal method when concentrations were decreasing.
| h*ng/mL | Males (Combined) | Females (Combined) |
|---|---|---|
| AUC From Time Zero to Time of Last Quantifiable Concentration (AUC0-t) of Apremilast by Sex | 2634 ± 24.5 | 3382 ± 38.2 |
The lower limit of quantitation for apremilast plasma concentrations was 1.0 ng/mL.
| h*ng/mL | Young: Apremilast | Elderly: Apremilast |
|---|---|---|
| Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-∞) of Apremilast | 2900 ± 28.7 | 3323 ± 41.8 |
The lower limit of quantitation for apremilast plasma concentrations was 1.0 ng/mL.
| h*ng/mL | Males (Combined) | Females (Combined) |
|---|---|---|
| AUC From Time Zero Extrapolated to Infinity (AUC0-∞) of Apremilast by Sex | 2673 ± 24.8 | 3499 ± 39.1 |
The lower limit of quantitation for apremilast plasma concentrations was 1.0 ng/mL.
| ng/mL | Young: Apremilast | Elderly: Apremilast |
|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Apremilast | 302 ± 26.8 | 321 ± 27.8 |
The lower limit of quantitation for apremilast plasma concentrations was 1.0 ng/mL.
| ng/mL | Males (Combined) | Females (Combined) |
|---|---|---|
| Maximum Observed Plasma Concentration of Apremilast by Sex | 299 ± 16.6 | 322 ± 33.5 |
The lower limit of quantitation for apremilast plasma concentrations was 1.0 ng/mL.
| hours | Young: Apremilast | Elderly: Apremilast |
|---|---|---|
| Time to Maximum Observed Plasma Concentration (Tmax) of Apremilast | 2.50 (0.5 to 5.0) | 2.50 (1.0 to 5.1) |
The lower limit of quantitation for apremilast plasma concentrations was 1.0 ng/mL.
| hours | Males (Combined) | Females (Combined) |
|---|---|---|
| Time to Maximum Observed Plasma Concentration (Tmax) of Apremilast by Sex | 2.5 (0.5 to 5.0) | 2.75 (1.0 to 5.1) |
| hours | Young: Apremilast | Elderly: Apremilast |
|---|---|---|
| Estimate of Terminal Elimination Half-life of Apremilast in Plasma (t1/2) | 9.41 ± 2.65 | 9.15 ± 2.56 |
| hours | Males (Combined) | Females (Combined) |
|---|---|---|
| Estimate of Terminal Elimination Half-life of Apremilast in Plasma by Sex | 8.06 ± 1.72 | 10.3 ± 2.76 |
| L/hr | Young: Apremilast | Elderly: Apremilast |
|---|---|---|
| Apparent Total Plasma Clearance When Dosed Orally (CL/F) of Apremilast | 10.4 ± 28.7 | 9.03 ± 41.8 |
| L/hr | Males (Combined) | Females (Combined) |
|---|---|---|
| Apparent Total Plasma Clearance When Dosed Orally of Apremilast by Sex | 11.2 ± 24.8 | 8.57 ± 39.1 |
| liters | Young: Apremilast | Elderly: Apremilast |
|---|---|---|
| Apparent Total Volume of Distribution When Dosed Orally (Vz/F) of Apremilast | 136 ± 38.9 | 115 ± 35.3 |
| liters | Males (Combined) | Females (Combined) |
|---|---|---|
| Apparent Total Volume of Distribution When Dosed Orally (Vz/F) of Apremilast by Sex | 128 ± 30.7 | 123 ± 43.4 |
Collected over From first dose of apremilast up to 11 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Young Males | — | 0/8 (0%) | 2/8 (25%) |
| Young Females | — | 0/10 (0%) | 1/10 (10%) |
| Young (Total) | — | 0/18 (0%) | 3/18 (16.7%) |
| Elderly Males | — | 0/8 (0%) | 2/8 (25%) |
| Elderly Females | — | 0/10 (0%) | 5/10 (50%) |
| Elderly (Total) | — | 0/18 (0%) | 7/18 (38.9%) |
| Overall Total | — | 0/36 (0%) | 10/36 (27.8%) |
| Event | Young Males | Young Females | Young (Total) | Elderly Males | Elderly Females | Elderly (Total) | Overall Total |
|---|---|---|---|---|---|---|---|
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 0/8 | 0/10 | 0/18 | 0/8 | 2/10 | 2/18 | 2/36 |
| CONSTIPATIONGastrointestinal disorders | 0/8 | 0/10 | 0/18 | 1/8 | 0/10 | 1/18 | 1/36 |
| HEADACHENervous system disorders | 1/8 | 0/10 | 1/18 | 0/8 | 0/10 | 0/18 | 1/36 |
| SOMNOLENCENervous system disorders | 1/8 | 0/10 | 1/18 | 0/8 | 0/10 | 0/18 | 1/36 |
| PHLEBITISVascular disorders | 0/8 | 0/10 | 0/18 | 1/8 | 0/10 | 1/18 | 1/36 |
| NAUSEAGastrointestinal disorders | 0/8 | 1/10 | 1/18 | 0/8 | 1/10 | 1/18 | 2/36 |
| TOOTHACHEGastrointestinal disorders | 0/8 | 0/10 | 0/18 | 0/8 | 1/10 | 1/18 | 1/36 |
| VOMITINGGastrointestinal disorders | 0/8 | 1/10 | 1/18 | 0/8 | 0/10 | 0/18 | 1/36 |
| PAINGeneral disorders | 0/8 | 0/10 | 0/18 | 0/8 | 1/10 | 1/18 | 1/36 |
| ARTHRALGIAMusculoskeletal and connective tissue disorders | 0/8 | 0/10 | 0/18 | 0/8 | 1/10 | 1/18 | 1/36 |
| Age, Continuous(years) | Young Males | Young Females | Elderly Males | Elderly Females | Total |
|---|---|---|---|---|---|
| Mean | 33.3 ± 7.48 | 35.2 ± 7.19 | 70.4 ± 3.62 | 70.6 ± 4.72 | 52.4 ± 19.23 |
| Sex: Female, Male(Participants) | Young Males | Young Females | Elderly Males | Elderly Females | Total |
|---|---|---|---|---|---|
| Female | 0 | 10 | 0 | 10 | 20 |
| Male | 8 | 0 | 8 | 0 | 16 |
| Ethnicity (NIH/OMB)(Participants) | Young Males | Young Females | Elderly Males | Elderly Females | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 2 | 0 | 0 | 2 |
| Not Hispanic or Latino | 8 | 8 | 8 | 10 | 34 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Young Males | Young Females | Elderly Males | Elderly Females | Total |
|---|---|---|---|---|---|
| White | 4 | 4 | 8 | 8 | 24 |
| Black or African American | 3 | 6 | 0 | 2 | 11 |
| Other | 1 | 0 | 0 | 0 | 1 |
| Body Mass Index (BMI)(kg/m^2) | Young Males | Young Females | Elderly Males | Elderly Females | Total |
|---|---|---|---|---|---|
| Mean | 26.6 ± 2.43 | 27.5 ± 2.59 | 26.3 ± 2.69 | 27.1 ± 2.42 | 26.9 ± 2.47 |
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
Data sharing details ↗ · www.amgen.com
Ran from Feb 2012 to primary completion in Mar 2012, 1 month.
Results were first posted in Apr 2021, 9 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Apremilast